6CM
VTVT icon

683 Capital Management’s vTv Therapeutics VTVT Stock Holding History

683 Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$635K Sell
16,000
-2,268
-12% -$82.3K 0.03% 168
2025
Q4 		$731K Buy
+18,268
New +$509K 0.03% 168

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

683 Capital Management's VTVT Position: Q1 2026 in Review

683 Capital Management reduced its vTv Therapeutics (VTVT) stake by 12% in Q1 2026, selling an estimated $82.3K and leaving 16,000 shares worth $635K. The position accounts for 0.03% of the portfolio, ranked #168.

683 Capital Management first reported a position in VTVT in Q4 2025 and has held it in 2 quarters since. The position peaked at $731K in Q4 2025. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • 683 Capital Management held 16,000 shares of vTv Therapeutics worth $635K as of Q1 2026.
  • 683 Capital Management sold 2,268 vTv Therapeutics shares in Q1 2026, an estimated $82.3K.
  • vTv Therapeutics made up 0.03% of 683 Capital Management's portfolio in Q1 2026, its #168 holding.
  • 683 Capital Management first reported a position in vTv Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's vTv Therapeutics position peaked at $731K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.